Circulating Tumor DNA Predicts Early Recurrence Following Locoregional Therapy for Oligometastatic Colorectal Cancer
C. O'Donnell(Mayo Clinic in Arizona), Zhaohui Jin(XinHua Hospital), Madison Conces(University Hospitals Seidman Cancer Center), Michael H. Storandt(Mayo Clinic in Arizona), J. Eva Selfridge(University Hospitals of Cleveland), Kevin Zablonski(University Hospitals of Cleveland), Teerada Siripoon(Mahidol University), Cornelius A. Thiels(Mayo Clinic in Arizona), Christopher L. Hallemeier(Mayo Clinic in Arizona), Susanne G. Warner(Pancreas Centre (Canada)), Thomas D. Atwell(Mayo Clinic), Nikolas Naleid(University Hospitals of Cleveland), David L. Bajor(University Hospitals of Cleveland), Krishan R. Jethwa(Mayo Clinic), Amit Mahipal(Dana-Farber Cancer Institute), Jessica L. Mitchell(Mayo Clinic), Patrick Starlinger(Mayo Clinic)
Cited by 4
Related Papers
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
|Journal of Clinical Oncology|2016|859
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530